Download PDF

1. Company Snapshot

1.a. Company Description

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.The company was incorporated in 1990 and is headquartered in Foster City, California.

Show Full description

1.b. Last Insights on GERN

Breaking News: Geron Corporation recently granted stock options to purchase 855000 shares of common stock to nine newly hired employees as an inducement for employment The grants were made effective April 17 2026 No recent earnings release was found Geron Corporations last reported earnings on February 29 2024 reported a net loss of 022 per share Some analysts have a hold rating on the stock given by Zacks Investment Research

1.c. Company Highlights

2. Geron's 2025 Earnings: A Year of Strategic Alignment

Geron Corporation's financial performance in 2025 reflected the company's efforts to become a more commercially minded organization, with a focus on its lead product, Rytelo. The company's revenue growth was driven by the increasing adoption of Rytelo, with a 9% demand growth in the fourth quarter compared to the third quarter. However, the actual EPS came out at '-0.05', relative to estimates at '-0.03', indicating a wider loss than expected. The company's operating expenses were managed effectively, with a projected reduction in total operating expenses in 2026 to between $230 million and $240 million.

Publication Date: Mar -01

📋 Highlights
  • Strategic Realignment for Growth: Geron's 2025 initiatives positioned the company for 2026 expansion, focusing on becoming a hematology leader.
  • Rytelo's Q4 Demand Growth: Achieved 9% demand growth and 150 new prescribing accounts, expanding to 1,300 total accounts.
  • 2026 Operating Expenses: Projected at $230–240 million, reflecting a $20 million reduction YoY to prioritize value-driven investments.
  • Target Patient Pool: Focused on 8,000 second-line lower-risk MDS patients, leveraging growth post-luspatercept treatment.
  • Path to Profitability: Management confirmed a long-term breakeven trajectory but emphasized 2026 focus on strategic investments, not immediate profitability.

Revenue Growth and Commercial Strategy

The growth strategy for Rytelo is built on three initiatives, with a focus on increasing awareness and education among U.S. healthcare professionals. Ahmed ElNawawi, Chief Commercial Officer, highlighted that Rytelo's performance in 2025 establishes a solid base for the company to execute its commercial strategy and further grow demand in 2026. The company's commercial execution is focused on identifying appropriate second-line patients faster, with a refined engagement plan. As Harout Semerjian, CEO, mentioned, "We are not going to comment on Q1, but what we have seen from IQVIA and others is in line with our expectation."

Valuation and Growth Expectations

Analysts estimate Geron's revenue growth at 44.1% next year, indicating a significant increase in adoption. With a current P/S Ratio of 5.83, the market is pricing in a certain level of growth. However, the company's ROE is -34.31%, and the Net Debt / EBITDA is 2.02, indicating a challenging financial situation. The EV/EBITDA ratio is -25.25, suggesting that the company's enterprise value is not justified by its EBITDA. As the company focuses on making the right investments to drive near and long-term value, investors will be watching the execution of its commercial strategy closely.

European Approval and Future Prospects

Geron has received European approval for Rytelo, which provides an opportunity for growth outside the U.S. However, as Harout Semerjian noted, "approval without funding is limited," and the company needs to understand the impact of the HTA piece and the MFN. The company's focus remains on its U.S. growth, while being opportunistic about Europe. With a strong balance sheet and a streamlined organization, Geron is well-positioned to execute its plans and drive growth in 2026.

3. NewsRoom

Card image cap

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr -20

Source: globenewswire.com

Card image cap

Geron Highlights RYTELO Launch, 2026 Revenue Outlook and Phase 3 Myelofibrosis Plans at Needham Conf

Apr -15

Source: defenseworld.net

Card image cap

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr -14

Source: globenewswire.com

Card image cap

Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary

Apr -13

Source: globenewswire.com

Card image cap

Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference

Apr -06

Source: globenewswire.com

Card image cap

Geron (NASDAQ:GERN) Share Price Passes Above 200 Day Moving Average – What’s Next?

Mar -31

Source: defenseworld.net

Card image cap

Geron Announces Appointment of New Members to its Board of Directors

Mar -26

Source: globenewswire.com

Card image cap

Geron Corporation (NASDAQ:GERN) Given Average Recommendation of “Hold” by Analysts

Mar -22

Source: defenseworld.net

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (25.00%)

6. Segments

Development of Therapeutic Products for Oncology

Expected Growth: 28.0%

The oncology market is expected to grow rapidly due to the increasing incidence of cancer and the need for innovative treatments. Geron Corporation's focus on developing therapeutic products for oncology is expected to drive revenue growth. The company's strong pipeline and expertise in this area will help in expanding its market share, driving growth above the global average of 25%. The increasing adoption of targeted therapies will also contribute to the growth.

7. Detailed Products

Imetelstat

A telomerase inhibitor that targets cancer stem cells, which are thought to be responsible for the initiation and progression of cancer.

GRN163L

A telomerase inhibitor that targets cancer stem cells, which are thought to be responsible for the initiation and progression of cancer.

GRN163

A telomerase inhibitor that targets cancer stem cells, which are thought to be responsible for the initiation and progression of cancer.

8. Geron Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

Geron Corporation's products are highly specialized and have limited substitutes, reducing the threat of substitutes.

Bargaining Power Of Customers

Geron Corporation's customers have limited bargaining power due to the company's strong brand reputation and limited alternatives.

Bargaining Power Of Suppliers

Geron Corporation's suppliers have moderate bargaining power due to the company's dependence on a few key suppliers for raw materials.

Threat Of New Entrants

The biotechnology industry is highly competitive, and new entrants can easily disrupt the market, posing a significant threat to Geron Corporation.

Intensity Of Rivalry

The biotechnology industry is highly competitive, and Geron Corporation faces intense rivalry from established players, leading to a high level of competition.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 25.06%
Debt Cost 6.68%
Equity Weight 74.94%
Equity Cost 6.68%
WACC 6.68%
Leverage 33.43%

11. Quality Control: Geron Corporation passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
ACADIA Pharmaceuticals

A-Score: 5.6/10

Value: 2.1

Growth: 9.0

Quality: 9.1

Yield: 0.0

Momentum: 9.0

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
Revolution Medicines

A-Score: 4.3/10

Value: 6.2

Growth: 1.8

Quality: 4.5

Yield: 0.0

Momentum: 9.0

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
TG Therapeutics

A-Score: 4.2/10

Value: 2.0

Growth: 8.1

Quality: 7.7

Yield: 0.0

Momentum: 4.5

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Janux Therapeutics

A-Score: 3.3/10

Value: 7.8

Growth: 3.4

Quality: 4.1

Yield: 0.0

Momentum: 3.5

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Geron

A-Score: 3.1/10

Value: 6.8

Growth: 5.2

Quality: 4.8

Yield: 0.0

Momentum: 0.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Iovance Bio

A-Score: 3.1/10

Value: 7.9

Growth: 5.7

Quality: 4.0

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

1.5$

Current Price

1.5$

Potential

-0.00%

Expected Cash-Flows